News
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also ...
We recently published a list of the 10 Innovative Healthcare Stocks to Watch in 2025. In this article, we are going to take a ...
Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other profitable dividend stocks. Amid growing concerns about economic growth and President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback